 | |
| Combination of | |
|---|---|
| Bupropion | Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist |
| Zonisamide | Sulfonamide anticonvulsant |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| (verify) | |
Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.123 Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.1 The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.145
References
References
- "Bupropion/Zonisamide - AdisInsight".
- "Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half". Archived from the original on 2010-01-11. Retrieved 2010-01-07.
- "Empatic Obesity Drug Information and News". Archived from the original on 2017-07-02. Retrieved 2010-01-07.
- Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
- Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.